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Abstract This paper aims to demonstrate the positive 
effect of a Lean Management (LM) approach to increasing 
efficiency, even in a company which is subject to critical 
market issues. The pharmaceutical industry is a well-
known example of a crisis-affected context and 
companies have directed attention to Lean Management 
for a long time, but they are stable in increasing 
effectiveness. This research uses a case study to move the 
attention to efficiency as an attractive LM goal. 
 
The result of this study provides a reference for academia 
as well as the business field. 
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1. Introduction 
 
The pharmaceutical industry has been greatly affected by 
the 2008-2010 global economic crisis. Moreover, recent 
specific trends may likely weaken companies more and 
more. Therefore, it may be necessary to push researchers 
and practitioners to establish improved approaches 
which are suitable for the industry [1, 2]. It is now widely 
accepted that Lean Management is of considerable benefit 
in manufacturing, so there is growing interest in it among 
companies in the pharmaceutical industry.  
 
It can be said that most of the companies are still working 
on developing their effectiveness (TPM and TQM) rather 
than focusing on efficiency. This means that they are 
trying to build stable running machines and stable 
processes [3, 4] before targeting the objective of achieving 
a low inventory. 
 
The aim of this paper is to present a case study of a 
pharmaceutical company that has focused on efficiency 
improvement. The goal is to determine strength as well to 
identify critical issues and to collect lessons learned about 
the correct approach that specific industries should 
adopt. In the case study, a Lean Management approach 
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was pursued through the re-engineering of the 
production flow and the implementation of a pull-based 
system. Results from the case study show that it was a 
successful choice: efficiency KPIs, Works in Process, Cycle 
Time, etc. were dramatically improved. 
 
The paper is structured as follows: section 2 is devoted to 
presenting the context and the state of the art of Lean 
Management in the pharmaceutical industry. In section 3, 
a case study is presented and discussed. Section 4 
provides some final remarks. 
 
2. Lean Management in the pharmaceutical industry 
 
According to IMS (Intercontinental Marketing Services) 
the global pharmaceutical industry will be worth 
US$1.160 billion in 2016 [5].A number of researchers and 
organizations [6] have identified the following key 
developments and issues in the industry: 
• Shifts in the growth of pharmerging countries (Figure 
1 and 2) 
• The expiration of patents of products which were 
launched during the industry's 'golden era' in the 
1990s and the progressive introduction of less 
expensive generic alternatives 
• A common strategy of industrial concentration 
which has been adopted in order to deal with the 
growing costs of R&D 
 
 
Figure 1. Global pharmaceutical market (% of total size) 
 
 
Figure 2. Global pharmaceutical market growth (billions of 
dollars and average annual growth rate) 
All these issues have contributed to the present 
framework of the industry, in which revenues are 
decreasing because of competition from generic 
alternatives, while the costs of R&D are rising for [7] and 
competition is increasing. All these features push 
pharmaceutical companies to apply methodologies for 
performance improvement [8]. 
 
2.1 Literature review 
 
‘Lean Production’, or rather ’Lean Management’ is an 
intellectual approach consisting of a system of measures 
and methods which, when considered as a whole, have 
the potential to bring about a lean and, therefore, 
particularly competitive state in a company. The main 
fields of activity concerned are product development, the 
supply chain, shop floor management and, to a lesser 
extent, after-sales services [9]. There are multiple ways to 
combine the individual practices in order to represent the 
multi-dimensional nature of Lean Manufacturing [10], 
which is the reason for the considerable amount of 
literature on the topic. 
 
Following its dramatic successes in manufacturing in the 
pharmaceutical industry, many companies have chosen 
to implement a Lean Management approach in order to 
accomplish such goals as decreasing waiting time to 
release products onto the market, to reduce production 
waste, improve communication with end users and raise 
quality levels, both in the course of production and in 
testing laboratories. 
 
Most of the research work is aimed at supporting the 
implementation of Lean Management in the 
pharmaceutical industry: [11] states that Lean 
Management could transform the Pharma Industry. A 
more frequently covered topic is the current state of Lean 
Management implementation [12]. Some researchers have 
focused on typical contextual factors, such as plant size 
and company type, that have an influence on the degree 
of implementation of lean practices [13]. Others have 
identified some barriers to the success of Lean 
Management, as well as their potential mitigation [14]. 
Many others have worked on the financial returns on 
investments from Lean Management [15], as well as on 
the potential benefits of the operative parameters [16, 17, 
18]. 
 
Many authors have benefited from the application of 
Lean Manufacturing concepts to different pharmaceutical 
areas, such as R&D [19, 20], clinical laboratories [21] or 
clinical supply chains [22]. Finally, even harmonization 
with legal regulations, as represented by the 
requirements for Good Manufacturing Practice (cGMP,) 
has been studied [23]. 
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In most cases, Lean Management is analysed in 
combination with Six Sigma [24]. The idea for the 
research presented in the paper originated in the work of 
Goetzfried and Basu [25], who state that most of the 
companies are stable enough to work to achieve 
effectiveness goals using Lean Management. The 
literature is thus not lacking in references to Lean 
Management in the pharmaceutical industry, which can 
be consulted in order to increase efficiency. 
 
3. Case study 
 
In order to provide an example of how it is possible and 
convenient to shift attention from effectiveness to efficiency, 
we now present the case of a pharmaceutical company that 
is dealing with the challenges presented in section 2, and 
which has reaped large benefits by using targets for 
manufacturing operations. The case study concerns the plant 
of a primary multinational company of the pharmaceutical 
industry. This plant produces pharmaceutical products in a 
solid form (pills, tablets, capsules, etc.). The company has 
about 400 employees and its annual production adds up to 
about 100 million packages sold in the European market and 
to more than 100 markets globally. 
 
Since early 2000, the company has been conducting a 
project of concentrating the production in a few 
specialized plants. The plant we have analysed has been 
chosen to produce ‘growing‘ products. This means that in 
a few years it has increased its capacity in a dramatic way 
and its portfolio of products, as well as a reorganization 
and improvement of its production flows, have seen 
strong demand. 
 
3.1 Objectives 
 
The management has decided to implement a Lean 
Management approach, but the main focus has been on 
achieving efficiency through improvement activities 
which are aimed at: 
• Reducing set-up time 
• Deleting non-added value activities 
• Minimizing inventories 
• Decreasing balance delays 
 
Within the general improvement programme, we have 
focused on a specific project that has been developed in 
two synergic ways in a pilot production flow: 
1. Re-engineering of the production flow 
2. Implementing a pull-based production system 
 
Both methods have contributed to the following goals: 
• Total Pipeline Lead Time reduction 
• Throughput Time reduction 
• WIP (Work In Process) reduction 
• Layout re-design 
Concerning the latter goal, the main problem was an 
excessive walkthrough product, which divided 
production flow into different production areas. 
 
In the following sections we present the details of the 
activities the company has implemented on the pilot 
production line. These activities are characterized by a 
high level of technology and innovation, but which have 
never been reviewed under the Lean Management 
principles. This allows for an appreciation of the 
contribution of the methodology in terms of efficiency. 
 
3.2 Re-engineering of the production flow 
 
The process of drug manufacture (Figure 3) can be broken 
down into a series of steps:  
A. Dispensing: This includes the operations which are 
designed to select a portion of pharmaceutical raw 
materials that are weighed and transferred to clean 
containers. 
B. Blending: This is the amalgamation of all the 
ingredients. It can occur in a number of stages. 
C. Screening: This is done in order to pulverize the 
materials more effectively. 
D. Tableting: Here, each tablet is made by pressing the 
granules inside a die. 
E. Coating: This is a process of evenly covering particles 
with a substance by applying a series of thin layers. 
F. Packaging: This encloses products to protect them 
for distribution, storage, sale and use. 
 
 
Figure 3. the production flow 
 
The production flow is characterized as having a buffer 
just after the second blending for technical reasons. 
Moreover, cycle times up to the second blending were 
really similar and completely different from the second 
part of the flow. This creates the impression of a two 
stage production flow. 
WORKPLACES PRODUCTION FLOW 
A Dispensing 
B Blending 
C Screening 
D Compacting 
E Table ing 
F Coating 
G Packaging 
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In line with the Lean Management approach, the value 
stream map method was used in order to eliminate 
various kinds of waste, such as: 
• Inappropriate processes-unnecessary processing or 
procedures 
• Overproduction 
• Rework 
• Inventory and WIP 
• Material transportation and handling reduction 
 
On the other hand, the specific goal pursued by the re-
engineering of the production flow was a layout design. 
The goal includes some sub-objectives strongly linked to 
the Lean Management: 
• The creation of a continuous production flow 
• A minimum distance from the beginning to the end 
of the flow 
• Efficiency in the use of the space 
 
With reference to the creation of a continuous production 
flow, pharmaceutical manufacturing has traditionally been 
a batch-wise process. However, several factors (reduction 
of cost, improved process efficiency, optimal use of 
equipment, flexibility in production capacity) encourage 
the pharmaceutical industry to investigate the 
opportunities offered by continuous processes [26]. 
Various technological advances (as mentioned above in 
tableting and granulation phases) have made this possible. 
 
From an organizational point of view, the main obstacle 
to making the ow continuous was the presence of a 
bottleneck. According to Králová and Bielak [27], a 
production flow bottleneck can be individuated by 
calculating the average rate of utilization for each 
workplace with respect to the whole-system average of 
this rate. An operation with the minimal value of the rate 
of utilization is regarded as a bottleneck. In the case study 
the bottleneck was the tableting operation. The lower 
severity was for the packaging workplace. Both 
workplaces needed an expansion of capacity. 
 
In order to remove both bottlenecks, the production 
machines were replaced with machines that were more 
advanced, from a technological point of view. This 
allowed for: 
• Reducing cycle times, according to the goal of 
making the flow continuous 
• Reducing space (the new machines are smaller), 
according to the goals of reducing the walkthrough 
of the product and to achieve efficiency in the use of 
the space 
 
3.3 The pull-based production system implementation 
 
The production flow performs a pull-based production 
system in order to define the inventory level. However, a 
specific goal for the company was to reduce WIP (see 
section 3.1). That is why the implementation of a hybrid 
Kanban-CONWIP system (Constant Work in Progress) 
was carried out. 
 
The CONWIP system was introduced by Spearman, 
Woodruff and Hopp [28]. The basis of this system of 
operation is that, in order for parts to be admitted into the 
line, each part container should have a card attached to it. 
When a container is consumed at the end of the line, the 
card attached to it is returned to the beginning of the line, 
and is subsequently attached to a designated part 
container before being readmitted to the line. Thus, the 
consumed container is replenished upon completion of 
the designated part. CONWIP systems can achieve a 
lower WIP level than Kanban systems [20], because WIP 
is equal to the number of CONWIP cards in the system. 
 
According to [29], there are some benefits of controlling 
WIP, such as: 
• It limits the amount of material released into the 
system 
• The amount of material that needs to be scrapped or 
reworked is reduced, and financial losses from sales 
of a now inferior product are diminished 
• It reduces cycle time variability 
• Production systems have a degree of flexibility that 
is lost when large volumes of WIP remain in the 
physical system 
 
Sometimes it is possible to combine the benefits of a 
hybrid Kanban-CONWIP system. This is outlined in the 
case study in which the specific shape of the flow 
suggests that it could be split into two parts. One is 
controlled by a pure Kanban system (the focus being on 
the inventory level of each workplace), while the second 
is controlled by a mixed Kanban-CONWIP system (the 
focus here is also on WIP). 
 
In Figure 4 we reported the final result of the 
implementation of the pull-based production system. 
 
 
Figure 4. The production flow after the Kanban implementation 
 
Since a CONWIP system behaves as a push system inside a 
black box, each workstation will continue to process work 
as long as there is work in the queue in front of it. WIP will 
tend to accumulate in front of the bottleneck workstation. 
However, a queue explosion does not occur as it does in a 
push system, since card control limits total WIP [29]. 
A B C B C B D E F 
Circulation of kanban Release of authorisation 
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3.6 Analysis of results 
 
The re-engineering of the production flow through Lean 
Management and the implementation of both Kanban 
and CONWIP led to the following results after 90 days 
(Table 1): 
 
Goal Target Results 
Total Pipeline Lead Time 
Reduction 
6 days 5 days 
Throughput Time reduction 3 days 2 days 
WIP reduction 30% 37% 
Lay-out redesign (walkthrough 
reduction) 
300 mt 284 mt 
Table 1. Results after 90 days 
 
4. Conclusions 
 
In this paper the authors have presented a successful case 
of Lean Management implementation in the 
pharmaceutical industry. The case has been chosen 
because the company has been using operational re-
organization/re-engineering for several years due to the 
new context of the pharmaceutical industry. Moreover 
the company has chosen to focus on efficiency 
improvement. The results show that it is possible to 
create a competitive advantage in this way. Practical 
remarks about the case study provide the opportunity to 
perform a continuous production flow instead of a batch 
flow and in order to control the production flow. 
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